Lenvatinib

Generic Name
Lenvatinib
Brand Names
Lenvima 10, Kisplyx, Lenvima
Drug Type
Small Molecule
Chemical Formula
C21H19ClN4O4
CAS Number
417716-92-8
Unique Ingredient Identifier
EE083865G2
Background

Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular ...

Indication

Lenvatinib is indicated for the treatment of the following cancerous conditions:

Differentiated Thyroid Cancer (DTC)

Renal Cell Carcinoma (RCC)

Hepatocellular Carcinoma (HCC)

Endometrial Carcinoma

Associated Conditions
Advanced Renal Cell Carcinoma, Endometrial Carcinoma, Unresectable Hepatocellular Carcinoma (HCC), Progressive, locally advanced radioactive iodine-refractory Differentiated Thyroid Cancer (DTC), Progressive, metastatic radioactive iodine-refractory Differentiated Thyroid Cancer (DTC)
Associated Therapies
-
Clinical Trials
Related News

Envafolimab, Lenvatinib Combined With VP-16 in Platinum-resistant Recurrent Epithelial Ovarian Cancer

First Posted Date
2022-06-16
Last Posted Date
2022-06-16
Lead Sponsor
Zhongda Hospital
Target Recruit Count
20
Registration Number
NCT05422183
Locations
🇨🇳

Zhongda Hospital, Nanjing, Jiangsu, China

Envofolimab and Lenvatinib Combined With Gemcitabine Plus Cisplatin for Advanced BTC as First-Line Treatment(ENLIGHTEN)

First Posted Date
2022-06-08
Last Posted Date
2022-10-12
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
43
Registration Number
NCT05410197
Locations
🇨🇳

The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China

Cryoablation Combined With Tislelizumab Plus Lenvatinib in Patients With Melanoma Liver Metastasis

Phase 2
Recruiting
Conditions
Melanoma
Interventions
Drug: Tislelizumab
Drug: Lenvatinib
Drug: Cryoablation
First Posted Date
2022-06-06
Last Posted Date
2022-11-10
Lead Sponsor
Fudan University
Target Recruit Count
25
Registration Number
NCT05406466
Locations
🇨🇳

Fudan University Shanghai Cancer Center, Shanghai, China

Assessment of the Efficacy of Lenvatinib Versus Sorafenib in the Management of Advanced Hepatocellular Carcinoma

Not Applicable
Conditions
Hepatocellular Carcinoma
Interventions
Drug: Lenvatinib
First Posted Date
2022-05-26
Last Posted Date
2022-05-26
Lead Sponsor
Sir Salimullah Medical College Mitford Hospital
Target Recruit Count
70
Registration Number
NCT05391867
Locations
🇧🇩

Department of Hepatology, Dhaka, Bangladesh

🇧🇩

Sir Salimullah Medical College, Dhaka, Bangladesh

Study of Pembrolizumab, Lenvatinib and Chemotherapy Combination in First Line Extensive-stage Small Cell Lung Cancer

First Posted Date
2022-05-20
Last Posted Date
2024-02-20
Lead Sponsor
Fundación GECP
Target Recruit Count
85
Registration Number
NCT05384015
Locations
🇪🇸

Hospital General Universitario de Valencia, Valencia, Spain

🇪🇸

ICO Badalona, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain

🇪🇸

Hospitalario Universitario A Coruña, A Coruña, La Coruña, Spain

and more 15 locations

A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)

First Posted Date
2022-04-22
Last Posted Date
2024-12-02
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
120
Registration Number
NCT05342636
Locations
🇧🇷

ICESP - INSTITUTO DO CÂNCER DO ESTADO DE SÃO PAULO ( Site 2300), São Paulo, Sao Paulo, Brazil

🇫🇷

Hopital Claude Huriez - CHU de Lille ( Site 1100), Lille, Nord, France

🇫🇷

Centre Hospitalier Régional Universitaire de Brest - Hôpital Morvan ( Site 1104), Brest, Finistere, France

and more 43 locations

Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Study

First Posted Date
2022-04-14
Last Posted Date
2024-03-12
Lead Sponsor
NRG Oncology
Target Recruit Count
240
Registration Number
NCT05327686
Locations
🇺🇸

University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States

🇺🇸

Dayton Physicians LLC-Atrium, Franklin, Ohio, United States

🇺🇸

Miami Valley Cancer Care and Infusion, Greenville, Ohio, United States

and more 148 locations

An Open-label, Phase I/II Study of PLENA Regimen in Patients With Unresectable Pancreatic Cancer or BTC

First Posted Date
2022-04-14
Last Posted Date
2022-04-14
Lead Sponsor
Chinese PLA General Hospital
Target Recruit Count
65
Registration Number
NCT05327582
Locations
🇨🇳

Biotherapeutic Department of Chinese PLA General Hospital, Beijing, Beijing, China

A Phase II Study of AK104 Plus Lenvatinib and TACE in HCC

First Posted Date
2022-04-08
Last Posted Date
2022-08-15
Lead Sponsor
Akeso
Target Recruit Count
60
Registration Number
NCT05319431
Locations
🇨🇳

Henan Cancer Hospital, Zhengzhou, Henan, China

🇨🇳

The First Hospital of Beijing University, Beijing, Beijing, China

🇨🇳

Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China

and more 2 locations

A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)

First Posted Date
2022-04-08
Last Posted Date
2024-11-20
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
200
Registration Number
NCT05319730
Locations
🇨🇱

Clínica UC San Carlos de Apoquindo ( Site 4405), Santiago, Region M. De Santiago, Chile

🇮🇹

IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori"-Oncologia Medica ( Site 32, Meldola, Emilia-Romagna, Italy

🇨🇳

Chang Gung Memorial Hospital at Kaohsiung ( Site 4003), Kaohsiung Niao Sung Dist, Kaohsiung, Taiwan

and more 49 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy